Skip to main content

Korean Medical Device Regulation

Welcome to RAPath Korea — your plain-English guide to the Korean medical device regulatory system overseen by the Ministry of Food and Drug Safety (MFDS, 식품의약품안전처).

Regulatory Pathway Map

Click a phase to expand — each card links to the relevant section of this guide.

Getting Started
What is a Medical Device?
MFDS definition under the Medical Devices Act — scope, exclusions, and key terms.
Read definition
Getting Started
Regulatory Framework
MFDS structure, Medical Devices Act vs. In Vitro Diagnostics Act, and regulatory lifecycle.
View framework
Getting StartedKey step
Medical Devices Act vs. IVD Act
Korea has separate laws for general medical devices and IVDs — know which applies to your device.
View law comparison

What this site covers

Korea operates two primary statutes for medical devices:

  • Medical Devices Act (의료기기법) — medical devices classified as Grades I–IV
  • In Vitro Diagnostics Medical Devices Act (체외진단의료기기법) — IVD devices (effective May 2021)

Quick navigation

GoalStart here
New to Korean regulationStart Here → What is a medical device?
Getting a product to marketPre-Market → Classification
Foreign manufacturerGMP → Foreign Manufacturers
Post-market obligationsPost-Market → Overview
UDI registrationUDI-K Overview
## Disclaimer

This website is provided for informational purposes only and does not constitute legal, regulatory, or professional advice. Regulations and requirements change frequently. For the most current and authoritative information, always consult:

  • Official MFDS publications and guidance documents
  • The Korean Ministry of Food and Drug Safety website (www.mfds.go.kr)
  • Qualified regulatory professionals or consultants familiar with Korean medical device law

Regulatory Pathways and Timelines

Korea offers several pathways for medical device approval depending on device classification and risk profile:

  • Standard Review: Typical timeframe of 6–12 months for Grade II and III devices
  • Expedited Review: Available for priority devices, innovative technologies, and breakthrough devices
  • Conditional Approval: For devices meeting unmet clinical needs
  • Mutual Recognition: Products approved by recognized overseas regulators (FDA, CE mark) may follow streamlined processes

Review timelines vary based on completeness of submission, device complexity, and whether additional clinical data is required.

Regulatory Costs

Manufacturers should budget for:

  • Application fees (vary by device classification and review pathway)
  • GMP certification and inspection fees
  • Post-market surveillance and adverse event reporting fees
  • Annual registration and renewal fees

Fees are updated annually by MFDS. Consult the official MFDS fee schedule or a qualified regulatory professional for current costs.

Key Regulatory Distinctions

Domestic vs. Foreign Manufacturers: Foreign manufacturers must appoint a local importer/representative in Korea responsible for compliance, pharmacovigilance, and adverse event reporting. Domestic manufacturers retain direct responsibility with MFDS.

Key Timelines and Deadlines ​ Manufacturers should be aware of important regulatory timelines: • Standard review period: typically 6 months for Grade II–III devices • Expedited review available for priority devices and products addressing unmet medical needs • Post-market surveillance reports due annually • UDI registration must be completed before product launch

Official Resources ​ For the most current regulatory guidance and official information: • MFDS Official Website: www.mfds.go.kr • Medical Device Division contact information and inquiry procedures • Online submission portal for pre-market and post-market notifications